Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype
- 1 September 2020
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (9), 1178-1185
- https://doi.org/10.1016/j.annonc.2020.04.473
Abstract
No abstract availableFunding Information
- Prostate Cancer Foundation
- Astellas Pharma Global Development
This publication has 28 references indexed in Scilit:
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE TrialJournal of Clinical Oncology, 2016
- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerThe New England Journal of Medicine, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancerNature, 2015
- Enzalutamide in Metastatic Prostate Cancer before ChemotherapyThe New England Journal of Medicine, 2014
- A Gain-of-Function Mutation in DHT Synthesis in Castration-Resistant Prostate CancerCell, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyThe New England Journal of Medicine, 2013
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyThe New England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerThe New England Journal of Medicine, 2011
- Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established targetThe Lancet Oncology, 2009